Mai Mehanna, Hardik Mody, Joy C Hsu, Julia Quintanilha, Zachary L Taylor, Angela James, Binita Rajbanshi, Pooja Manchandani, Lakshmi Manasa Chekka
Omics biomarkers comprise several molecular entities, including genomic, epigenomic, transcriptomic, proteomic, and metabolomic signatures. They play an essential role in oncology drug development and clinical settings by enabling personalized medicine. In precision oncology, validating biomarkers is a greater challenge than discovering them. The biomarkers discussed here span a wide evidentiary spectrum, from those endorsed in clinical guidelines to those that remain investigational.